Upcoming Clinical Data Will Reshape Immuno-Oncology Amid Uncertainties

Published
03 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$4.70
75.1% undervalued intrinsic discount
15 Aug
US$1.17
Loading
1Y
-19.3%
7D
9.3%

Author's Valuation

US$4.7

75.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 0.36%

Shared on24 Apr 25
Fair value Decreased 4.62%

Shared on17 Apr 25
Fair value Increased 4.84%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.

Shared on09 Apr 25
Fair value Decreased 2.63%